Survodutide (BI 456906) 5ml

Ebs Pharma Sa Survodutide (BI 456906) is a once-weekly injectable dual glucagon/GLP-1 receptor agonist developed for treating obesity and MASH (metabolic dysfunction-associated steatohepatitis). It acts as a glucagon analog to reduce appetite and increase energy expenditure showing up to 18.7% weight loss.
Key Aspects of Survodutide:
Mechanism of Action: It is a dual agonist that activates both the glucagon receptor and the GLP-1 receptor, distinguishing it from treatments solely targeting GLP-1 (like semaglutide). This dual action may lead to higher efficacy in weight loss and reduction of liver fat.
Clinical Efficacy (Obesity): Data indicates significant, dose-dependent weight loss in participants with a BMI ≥ 27 kg/m², with some participants losing up to 18.7% of their body weight at 46 weeks.
Treatment for MASH: The drug is being evaluated for MASH and liver fibrosis, with studies showing it reduces liver inflammation, fibrosis, and fat.
Safety and Side Effects: Similar to other GLP-1 based therapies, the most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation.
Dosage:
1ml once a week subcutaneously